ClinicalTrials.gg
CompletedNCT03056209Updated Apr 27, 2018

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

A Phase 1 interventional study of KL1333 25 mg and KL1333 50 mg in MELAS Syndrome and Mitochondrial Respiratory Chain Deficiencies, sponsored by Yungjin Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-27.

Sponsored by Yungjin Pharm. Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.

02

Conditions studied

  • MELAS Syndrome
  • Mitochondrial Respiratory Chain Deficiencies

Keywords

  • Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
03

In context

MELAS Syndrome

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's enrollment of 60 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Yungjin Pharm. Co., Ltd. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 - 45 years of age at the time of screening
  • Subjects weighing ≥55 and ≤90 kg with between 18 and 27 kg/m2
  • Subjects who agreed to voluntarily participate in this study and comply with all the study requirements by signing form after being informed of the nature of this study and understanding all aspects of this study

Exclusion criteria

Exclusion Criteria:

  • History of hepatic, renal, neurologic, immunologic, respiratory, endocrine disease or hematologic•oncologic disease, cardiovascular, psychiatric disease
  • History of disease or surgery of the gastrointestinal tract that could interfere with kinetics of the study drug. Simple hernia repair or appendectomy are excepted.
  • History of clinically significant or relevant allergy/
  • Blood (SGOT), ALT (SGPT) >1.5 of upper limit
  • value of ≤90mL/min/1.73m2
  • Systolic blood pressure of \<100 mmHg or >160 mmHg
  • Diastolic blood pressure of \<60 mmHg or >100 mmHg
  • Any abnormalities in 12-lead at screening visit
  • Subjects who showed positive result in drug abuse tests, or who has history of drug abuse within 60 days prior to the time of screening
  • Subjects who took prescribed medications or oriental medicine within 14 days or over-the-counter (OTC) medications or vitamins within 7 days prior to the dose of the study drug (however, the subject can be included if other criteria are met according to the discretion of the investigator)
  • Subjects who were administered any products within 3 months from the first dose of the study drug
  • Subjects who have donated whole blood (60 days) or partial blood (30 days), or received blood transfusion
  • Subjects who have had alcohol consistently (>21units/week, 1unit=10 g of pure alcohol) or who is not able to stop drinking alcohol throughout the study period
  • Subjects who have smoked until 90 days prior to the study initiation or who are not able to stop smoking throughout the study period
  • Subjects who are not able to stop taking grapefruit/caffeine from 3 days prior to the first dose of the study drug throughout the study period
  • Subjects who plan for pregnancy during the study period or who are not able to use established method
  • Subject who judged not eligible for study participation by investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    KL1333 25mg

    Group 1

    Drug: KL1333 25 mg · Drug: Placebo

  • Experimental
    KL1333 50mg

    Group 2

    Drug: KL1333 50 mg · Drug: Placebo

  • Experimental
    KL1333 100mg

    Group 3

    Drug: KL1333 100 mg · Drug: Placebo

  • Experimental
    KL1333 200mg

    Group 4

    Drug: KL1333 200 mg · Drug: Placebo

  • Experimental
    KL1333 400mg

    Group 5

    Drug: KL1333 400 mg · Drug: Placebo

  • Experimental
    KL1333 600mg

    Group 6

    Drug: KL1333 600 mg · Drug: Placebo

  • Experimental
    KL1333 800mg

    Group 7

    Drug: KL1333 800 mg · Drug: Placebo

Interventions

  • oral administration, single dose, 25 mg 1 tab

  • oral administration, single dose, 25 mg 2 tabs

  • oral administration, single dose, 100 mg 1 tab

  • oral administration, single dose, 100 mg 2 tabs

  • oral administration, single dose, 100 mg 4 tabs

  • oral administration, single dose, 100 mg 6 tabs

  • oral administration, single dose, 100 mg 8 tabs

  • DrugPlacebo

    oral administration, placebo

06

What researchers measure

Primary outcomes

  1. Number of reported adverse events

    Time frame: from day 1 to day 15

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of KL1333

    Time frame: from day 1 to day 15

  2. Area Under the Curve (AUC) of KL1333

    Time frame: from day 1 to day 15

  3. Half-life (T1/2) of KL1333

    Time frame: from day 1 to day 15

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Jongno-gu 110744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Apr 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2017
First posted
Feb 17, 2017
StartActual
Jun 26, 2017
Primary completionActual
Apr 16, 2018
CompletionActual
Apr 16, 2018
Last update
Apr 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03056209
Lead sponsor
Yungjin Pharm. Co., Ltd.
Responsible party
Sponsor
First posted
Feb 17, 2017
Start date
Jun 26, 2017
Primary completion
Apr 16, 2018
Completion
Apr 16, 2018
Last update
Apr 27, 2018

Study contacts

Kyung-Sang Yu, MD., MBA
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Napazimone

Start the discussion